Who
Christy J. Oliger
Director
Company insider
Files Form 4 as: Director, Zenas BioPharma; Director, Bicara Therapeutics; Director, Nuvalent; Director, Karyopharm Therapeutics; Director, Vera Therapeutics; Director, Replimune Group; Director, LAVA Therapeutics NV; Director, RayzeBio.
In numbers
- Trades disclosed
- 55
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 10
- Companies where not an officer
- 10
- First trade
- 28 Aug 2020
- Last trade
- 1 Sep 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 2 Sep 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,000 at $0.00 | filing |
| 1 Sep 2026filed 2 Sep 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,000 at $0.00 | filing |
| 28 Jul 2026filed 29 Jul 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,950 at $0.00 | filing |
| 28 Jul 2026filed 29 Jul 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,950 at $0.00 | filing |
| 15 Jul 2026filed 15 Jul 2026 | NuvalentBiotechnology | SEC FORM 4 Code U | $164K1,324 at $124.00 | filing |
| 15 Jul 2026filed 15 Jul 2026 | NuvalentBiotechnology | SEC FORM 4 Code D | —6,091 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalentoption or derivative · Biotechnology | SEC FORM 4 Code D | —6,119 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalentoption or derivative | SEC FORM 4 Code D | —6,119 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalent | SEC FORM 4 Code U | $164K1,324 at $124.00 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalent | SEC FORM 4 Code D | —6,091 | filing |
| 16 Jun 2026filed 18 Jun 2026 | NuvalentBiotechnology | SEC FORM 4 Code A | —3,444 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | Nuvalent | SEC FORM 4 Code A | —3,444 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,508 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,508 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,084 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,084 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,500 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,500 at $0.00 | filing |
| 13 Nov 2025filed 17 Nov 2025 | LAVA Therapeutics NVoption or derivative | SEC FORM 4 Code D | —33,390 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | Nuvalentoption or derivative | SEC FORM 4 Code A | —6,119 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.